Follicular Lymphoma Clinical Trials

A listing of 62 Follicular Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Follicular Lymphoma

13 - 24 of 62

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 62 active clinical trials seeking participants for Follicular Lymphoma research studies. The states with the highest number of trials for Follicular Lymphoma participants are Texas, California, New York and Florida.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona +17 locations

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Learn More ›

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

NCT06792825

Recruiting

The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL) and marginal zone lymphoma (MZ). Each cohort, FL and MZ, will be evaluated separately. This study is presented to the patient and consent is signed prior to the initiation of treatment for their primary malignancy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/07/2025

Locations: Masonic Cancer Center, Minneapolis, Minnesota

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma

Learn More ›

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

NCT05653271

Recruiting

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/06/2025

Locations: AdventHealth Orlando, Orlando, Florida +12 locations

Conditions: B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, High-grade B-cell Lymphoma

Learn More ›

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

NCT06340737

Recruiting

This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/04/2025

Locations: Stanford University, Palo Alto, California

Conditions: Follicular Lymphoma, Mantle Cell Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Large B-cell Lymphoma

Learn More ›

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

NCT06350318

Recruiting

The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/04/2025

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma

Learn More ›

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

NCT04246086

Recruiting

This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len vs subcutaneous (SC) mosunetuzumab + len.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/01/2025

Locations: City of Hope National Medical Center, Duarte, California +27 locations

City of Hope National Medical Center, Duarte, California

Fairview Hospital, Cleveland, Ohio

Cleveland Clinic, Cleveland, Ohio

Hillcrest Hospital, Mayfield Heights, Ohio

Tennessee Oncology;Chattanooga Oncology & Hematology Associates, Chattanooga, Tennessee

Tennessee Oncology PLLC - Franklin, Franklin, Tennessee

Swedish Medical Center, Seattle, Washington

the First Hospital of Jilin University, Changchun, Not set

Hunan Cancer Hospital, Changsha City, Not set

West China Hospital, Sichuan University, Chengdu, Not set

Fudan University Shanghai Cancer Center, Shanghai City, Not set

Tianjin Medical University Cancer Institute & Hospital, Tianjing, Not set

The First Affiliated Hospital of Xiamen University, Xiamen, Not set

CHRU de Lille - Hopital Claude Huriez, Lille, Not set

CHU Montpellier, Montpellier, Not set

Hôpital Saint-Louis, Paris, Not set

Centre Hospitalier Lyon Sud, Pierre Benite, Not set

CHU Rennes - Hopital Pontchaillou, Rennes cedex 09, Not set

Institut Claudius Regaud, Toulouse, Not set

Hospital Universitario Vall d Hebron, Barcelona, Not set

Hospital Universitario Fundacion Jimenez Diaz., Madrid, Not set

Hospital Universitario Virgen de la Victoria, Malaga, Not set

Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

University College London Hospitals NHS Foundation Trust - University College Hospital, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Freeman Hospital, Newcastle upon Tyne, Not set

Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, Not set

Oxford University Hospitals NHS Foundation Trust, Oxford, Not set

Conditions: Follicular Lymphoma

Learn More ›

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493

Recruiting

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to esta... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: Southern Cancer Center, Mobile, Alabama +208 locations

Southern Cancer Center, Mobile, Alabama

Arizona Oncology Associates - Tuscon-Rusadill Road, Tucson, Arizona

TOI - Clinical Research, Cerritos, California

UCSF Fresno, Clovis, California

UC San Diego Health Sciences, La Jolla, California

UCLA Clinical Research Unit Hematology/Oncology, Santa Monica, California

Rocky Mountain Cancer Centers (RMCC) - Boulder, Boulder, Colorado

St. Mary's Hospital and Regional Medical Center - St. Mary's, Grand Junction, Colorado

SCL Health Lutheran Medical Center, Greeley, Colorado

Cancer Specialists of North Florida, Fleming Island, Florida

Florida Cancer Specialists & Research Institute (FCS) - Fort Myers Cancer Center, Fort Myers, Florida

Mayo Clinic - Cancer Clinical Research Office, Jacksonville, Florida

Mayo Clinic, Jacksonville, Florida

Miami Cancer Institute, Miami, Florida

Florida Cancer Affiliates/Ocala Oncology - Clinic, Ocala, Florida

BRCR Medical Center, INC, Plantation, Florida

Florida Cancer Specialists, Saint Petersburg, Florida

Florida Cancer Specialists - Panhandle, Tallahassee, Florida

H Lee Moffitt Cancer Center and Research Institute I, Tampa, Florida

Florida Cancer Specialists & Research Institute (FCS) - Atlantis, West Palm Beach, Florida

Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii

University of Chicago, Chicago, Illinois

Illinois Cancer Specialists, Niles, Illinois

June E. Nylen Cancer Center, Sioux City, Iowa

The University of Kansas Cancer Center, Overland Park, Kansas

University of Maryland, Baltimore, Maryland

The office of Frederick P. Smith, MD, P.C., Chevy Chase, Maryland

Mass General Cancer Center at Newton-Wellesley, Newton, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

St. Joseph Mercy Hospital, Ypsilanti, Michigan

Mayo Clinic - Rochester, Rochester, Minnesota

Saint Louis University Cancer Center, Saint Louis, Missouri

University Of Nebraska Medical Center, Omaha, Nebraska

Astera Cancer Care, East Brunswick, New Jersey

Astera Cancer Center, East Brunswick, New Jersey

Regional Cancer Care Associates-Freehold, Freehold, New Jersey

Hackensack University Medical John Theurer Cancer Center, Hackensack, New Jersey

Regional Cancer Care Associates LLC - Howell, Howell, New Jersey

Regional Cancer Care Associates LLC - Little Silver, Little Silver, New Jersey

New Mexico Cancer Care Alliance, Albuquerque, New Mexico

New York Oncology Hematology, P.C., Albany, New York

Northwell Health/Monter Cancer Center, Lake Success, New York

Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York

Columbia U - Herbert Irving Comprehensive Cancer Center, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Hematology Oncology Associates of Rockland, P.C., Nyack, New York

Messino Cancer Center, Asheville, North Carolina

Levine Cancer Institute - Concord, Concord, North Carolina

FirstHealth of the Carolinas, Pinehurst, North Carolina

Gabrail Cancer Center Research, Canton, Ohio

Oncology Hematology Care (OHC), Inc. - Kenwood Office, Cincinnati, Ohio

Willamette Valley Cancer Institute and Research Center - Oncology, Eugene, Oregon

University of Pittsburgh Medical Center - Oncology, Pittsburgh, Pennsylvania

Western Pennsylvania Hospital Hematology & Cellular Therapy, Pittsburgh, Pennsylvania

Tennessee Oncology, PLLC, Chattanooga, Tennessee

University of Tennessee Medical Center - Cancer Institute, Knoxville, Tennessee

Sarah Cannon Research Institute, Nashville, Tennessee

Texas Oncology - Amarillo, Amarillo, Texas

Texas Oncology-Austin Midtown, Austin, Texas

Texas Oncology - Medical City Dallas Pediatric Hematology, Dallas, Texas

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Millennium Physicians - Oncology, Houston, Texas

Texas Oncology, Plano, Texas

Mays Cancer Center, San Antonio, Texas

UT Health East Texas HOPE Cancer Center - Tyler, Tyler, Texas

USO Texas Oncology - Tyler, Tyler, Texas

Texas Oncology- Weslaco, Weslaco, Texas

Utah Cancer Specialists/ IHO Corp, Salt Lake City, Utah

Huntsman Cancer Institute; The University of Utah, Salt Lake City, Utah

Peninsula Cancer Institute, Chesapeake, Virginia

Virginia Cancer Specialists, Gainesville, Virginia

Oncology and Hematology Associates of Southwest Virginia Inc., Roanoke, Virginia

MC Rockwood Cancer Bl Specialty Ctr - North, Spokane, Washington

Yakima Valley Memorial Hospital - North Star Lodge Cancer Center, Yakima, Washington

Wheeling Hospital, Wheeling, West Virginia

Royal Adelaide Hospital, Adelaide, South Australia

Flinders Medical Centre, Bedford Park, South Australia

Monash Health, Clayton, Victoria

Barwon Health, University Hospital Geelong, Geelong, Victoria

Hollywood Private Hospital, Nedlands, Western Australia

GenesisCare - St Andrew's, Adelaide, Not set

Peninsula Health - Frankston, Frankston, Not set

Royal Hobart Hospital, Hobart, Not set

Gold Coast University Hosptial, Southport, Not set

CHU Dinant Godinne UCL Namur, Yvoir, Namur

Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen

UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant

University Health Network Princess Margaret Hospital, Toronto, Ontario

Centre Hospitalier de l'Universite de Montreal (CHUM), Montréal, Quebec

Sir Mortimer B Davis/Jewish General Hospital, Montréal, Quebec

Fujian Medical University Union Hospital, Fuzhou, Fujian

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian

The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou

The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, Hangzhou

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei

Henan Provincial People's Hospital, Zhengzhou, Henan

Henan Cancer Hospital, Zhengzhou, Henan

Hunan Cancer Hospital, Changsha, Hunan

The First Bethune Hospital of Jilin University, Changchun, Jinlin

The Affiliated Hospital of Qingdao University, Qingdao, Shandong

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai

Shanxi Bethune Hospital, Taiyuan, Shanxi

Peking University Third Hospital, Beijing, Not set

Tongji Hospital of Tongji Medical College of HUST, Hangzhou, Not set

Jiangxi Cancer Hospital, Nanchang, Not set

Shandong Cancer Hospital, Shandong, Not set

Tongji Hospital of Tongji University, Shanghai, Not set

Sichuan Provincial People's Hospital, Sichuan, Not set

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set

Centre Hospitalier Universitaire de Bordeaux-Hopital du Haut Leveque, Pessac Cedex, Aquitaine

CHRU Brest Hôp Morvan, Brest, Bretagne

Institut Bergonie, Bordeaux, Gironde

Centre Hosp Mulh Hop Emile Muller, Mulhouse, Haut-Rhin

Centre Henri Becquerel, Rouen, Haute-Normandie

CHU de Limoges Dupuytren, Limoges, Haute-Vienne

CHU de Grenoble - Hopital Albe, La Tronche, Isere

CHU de Nantes - Hematologie, Nantes, Loire-Atlantique

CHRU de Lille Hop Claude Huriez, Lille, Nord

Centre Hospitalier Le Mans, Le Mans, Sarthe

Centre Hospitalier Universitaire D'Angers - Hématologie Clinique, Angers, Not set

CHRU de Besançon- Hopital Jean Minjoz, Besancon, Not set

CHU Caen, Caen, Not set

CHU de Clermont-Ferrand, site Estaing, Clermont-Ferrand, Not set

Centre Hospitalier Docteur Schaffner, Lens, Not set

L'Hôpital Privé Confluent, Nantes, Not set

L'hôpital Privé du Concluent, Nantes, Not set

Hopital Saint Louis, Paris, Not set

Centre Hospitalier Universitaire de Poitiers, Poitiers, Not set

Centre Hospitalier - Hôpital de jour d'Hématologie, Périgueux, Not set

CHU de Nancy Brabois, Vandœuvre-lès-Nancy, Not set

Centre Hospitalier Bretagne Atlantique, Vannes, Not set

Institut Gustave Roussy, Villejuif, Not set

Hopital Henri Mondor - Hemopathies Lymphoides, Créteil, Île-de-France

Diakoneo Diak Schwaebisch Hall gGmbH, Schwäbisch Hall, Baden-Württemberg

Klinikum Der Universität München AöR, München, Bayern

Klinikum rechts der Isar der Technischen Universitat Muenche, München, Bayern

Universitätsmedizin Mainz, Mainz, Hessen

Universitaetsklinikum Bonn AöR, Bonn, Nordrhein-Westfalen

Kliniken Maria Hilf GmbH, Moenchengladbach, Nordrhein-Westfalen

Städt. Krankenhaus Kiel, Kiel, Schleswig-Holstein

Vivantes Klinikum am Urban Hämatologie und Onkologie, Berlin, Not set

University Medical Center Schleswig Holstein, Kiel, Not set

Debreceni Egyetem Klinikai Központ, Debrecen, Hajdú-Bihar

Semmelweis Egyetem Általános Orvostudományi Kar, Budapest, Not set

Országos Onkológiai Intézet, Budapest, Not set

Del-pesti Centrumkorhaz Orszagos Hematologiai és Infektologiai Intezet, Budapest, Not set

AOU Federico II, Napoli, Campania

Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS, Meldola, Forli-Cesena

ASST Spedali Civili di Brescia, Brescia, Not set

PO Garibaldi-Nesima, ARNAS Garibaldi, Catania, Not set

AOU Careggi, Firenze, Not set

Ospedale Vito Fazzi, ASL Lecce, Lecce, Not set

IEO - Istituto Europeo di Oncologia, IRCCS, Milano, Not set

Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda, Milano, Not set

Ospedale Niguarda, ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

Ospedale San Gerardo, ASST di Monza, Monza, Not set

Ospedale Civile S.Spirito, PO di Pescara, AUSL Pescara, Pescara, Not set

Ospedale Infermi di Rimini, AUSL Rimini, Distretto di Rimini, Presidio di Rimini, Santarcangelo di Romagna e Novafeltria, Rimini, Not set

Catholic University Of Sacred Heart, Roma, Not set

PU Campus Bio-Medico di Roma, Roma, Not set

Regina Elena, Istituto Nazionale dei Tumori , IFO, IRCCS, Roma, Not set

Azienda Ospedaliera Santa Maria di Terni, Terni, Not set

Azienda Ospedaliera Ordine Mauriziano di Torino, Ospedale Umberto I di Torino, Torino, Not set

Ospedale S.Giacomo Apostolo, PO Castelfranco Veneto, AULSS 2 Marca Trevigiana, Treviso, Not set

Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI), Ospedale Maggiore, Trieste, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp]

Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Pusan National University Hospital, Busan, Not set

Gachon University Gil Medical Center, Incheon, Not set

Ajou University Hospital, Suwon, Not set

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Mazowieckie

Centrum Medyczne Pratia Poznan, Skorzewo, Wielkopolskie

Pratia Onkologia Katowice, Katowice, Not set

Pratia MCM Krakow, Kraków, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o., Słupsk, Not set

MICS Centrum Medyczne Torun, Torun, Not set

MTZ Clinical Research powered by Pratia, Warszawa, Not set

Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Not set

National Cancer Center Singapore, Singapore, Not set

Hospital Universitari Vall d'Hebrón, Barcelona, Cataluny

Hospital Costa del Sol, Marbella, Málaga

Hospital Del Mar, Barcelona, Not set

Hospital Univ. Infanta Leonor, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Clínica Universidad de Navarra, Madrid, Not set

C.H. de Navarra, Pamplona, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Nuestra Señora de Valme, Sevilla, Not set

Hospital Universitario Virgen De La Macarena, Sevilla, Not set

Buddihist Tzu Chi Medical Foundation- Hualien Tzu Chi Hospital, Hualien City, Not set

Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology, Kaohsiung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Ankara University Medical Faculty - Hematology, Ankara, Not set

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research, Ankara, Not set

Gazi University Medical Faculty, Ankara, Not set

Medipol Bagcilar Mega Hospital, Istanbul, Not set

Ondokuz Mayis University Medical Faculty - Hematology, Samsun, Not set

Western General Hospital - Haematology, Edinburgh, Edinburgh, City Of

Imperial College Healthcare NHS Trust - Hammersmith Hospital, London, London City

St Bartholomew's Hospital Barts Health NHS Trust, London, London, City Of

The Clatterbridge Cancer Centre NHS Foundation Trust - Clatterbridge Cancer Centre, Bebington, Not set

Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Cornwell, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Northwick Park Hospital Middlesex, United Kindgom, HA1 3UJ, Middlesex, Not set

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

Learn More ›

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT05602363

Recruiting

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2025

Locations: UC Irvine Health, Orange, California +10 locations

Conditions: B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

Learn More ›

64Cu-LLP2A for Imaging Hematologic Malignancies

NCT06636175

Recruiting

This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with nega... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Washington University School of Medicine, Saint Louis, Missouri

Conditions: Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia

Learn More ›

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

NCT04998669

Recruiting

The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/22/2025

Locations: Florida Cancer Specialists and Research Institute, Fort Myers, Florida +4 locations

Conditions: Follicular Lymphoma

Learn More ›

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019

Recruiting

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/22/2025

Locations: Banner Health - MD Anderson Cancer Center, Gilbert, Arizona +35 locations

Banner Health - MD Anderson Cancer Center, Gilbert, Arizona

Christiana Care Hospital - Helen F Graham Cancer Center, Newark, Delaware

Napa Research, Pompano Beach, Florida

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Regional Cancer Care Associates, Hackensack, New Jersey

Montefiore Medical Center, Bronx, New York

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Weill Cornell, New York City, New York

Duke University, Durham, North Carolina

Gabrail Cancer & Research Center, Canton, Ohio

The Ohio State University - The James Cancer Hospital, Columbus, Ohio

Oregon Health and Science University - Knight Cancer Institute, Portland, Oregon

Rhode Island Hospital, Providence, Rhode Island

University of Texas Southwestern, Dallas, Texas

Fred Hutchinson Cancer Center, Seattle, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

AP-HP Hôpital Henri-Mondor, Créteil, Not set

Institut Gustave Roussy, Villejuif, Not set

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo - Presidio Ospedaliero SS Antonio e Biagio e Cesare Arrigo, Ospedale Civile, Alessandria, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

IRCCS Ospedale San Raffaele, Milano, Not set

AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette, Torino, Not set

Azienda Ospedaliera - Universitaria Integrata di Verona - Ospedale Borgo Roma, Verona, Not set

Institute of Oncology, ARENSIA Exploratory Medicine, Chisinau, Not set

Uniwersyteckie Centrum Kliniczne, Osrodek Badan Klinicznych Wczesnych Faz, Gdańsk, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, Warszawa, Not set

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Łódź, Not set

ARENSIA Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest, Not set

ARENSIA Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca, Not set

Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Not set

Hospital Universitario Quironsalud Madrid, Madrid, Not set

START Madrid - CIOCC, Madrid, Not set

START Madrid - Hospital Fundacion Jimenez Diaz, Madrid, Not set

Clinica Universidad de Navarra - Pamplona, Pamplona, Not set

Hospital Clinico Universitario de Salamanca, Salamanca, Not set

ARENSIA Research Clinic at Harmony Health Clinic, Kyiv, Not set

Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma

Learn More ›

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319

Recruiting

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Grade 3b Follicular Lymphoma, Mantle Cell Lymphoma

Learn More ›

13 - 24 of 62